$GHRS News

Wells Fargo Initiates Coverage On GH Research with Overweight Rating, Announces Price Target of $44

H.C. Wainwright Maintains Buy Rating on GH Research (GHRS)

GH Research Announces Publication of Phase 2a Postpartum Depression Results

GH Research Announces Publication Of Full Results From Its Phase 2a Trial In Postpartum Depression

GH Research: Rapid Onset And Short Action Change The Treatment Paradigm

HC Wainwright & Co. Maintains Buy on GH Research, Lowers Price Target to $65

Assessing GH Research (GHRS) Valuation After Key Phase 2b Results And Phase 3 Trial Plans

These Analysts Revise Their Forecasts On GH Research After Q1 Results

Cantor Fitzgerald Maintains Overweight on GH Research, Raises Price Target to $35

Citizens Maintains Market Outperform on GH Research, Lowers Price Target to $39

GH Research Reports First Quarter 2026 Financial Results and Provides Business Update

GH Research Q1 EPS $(0.31) Misses $(0.28) Estimate

GH Research Announces Pricing of $117.5 Million Underwritten Offering

GH Research Prices ~$117.5M Offering Of 6.528M Shares At $18/Share

FDA Fast-Tracks Review of Some Psychedelic Drugs. This Stock Is Set to Benefit.

‘Can I have some, please?’: Trump jokes as he signs psychedelics order after Joe Rogan push. These stocks soar

How Trump Sent Psychedelics-Tied Compass Pathways And Others Flying

GH Research Welcomes White House Executive Order to Accelerate Medical Treatments for Serious Mental Illness

GH Research: WH Decision On Psychedelics To Treat Depression Makes Bull Case

Psychedelic stocks soar after Trump signs executive order to fast-track treatments